The merger agreement provides for Regeneron, through a subsidiary, to initiate a tender offer to acquire all outstanding shares of Checkmate at an all-cash price of $10.50 per share of Checkmate common stock. Food and Drug Administration or any other regulatory agency. Vidutolimod is an investigational therapy and has not been approved by U.S. In the Phase 1b program, documented abscopal responses were seen in distant, un-injected lesions. Vidutolimod is administered into the tumor and is believed to induce and expand anti-tumor T cells and induce tumor regression as a monotherapy in patients whose tumors previously progressed on PD-1 checkpoint inhibition. It is our hope that Regeneron's resources and expertise will help accelerate the development of vidutolimod and realization of the full potential of our virus-like particle (VLP) platform for immunotherapy," said Art Krieg, M.D., Checkmate's Founder and Chief Scientific Officer. "We believe that the data we have generated with vidutolimod positions Checkmate at the forefront of the innate immune activator field. "We are thrilled that Checkmate will become part of Regeneron, a biotechnology leader that shares our deep appreciation for science, hunger for ground-breaking discoveries and commitment to helping patients defeat cancer," said Alan Bash, President and Chief Executive Officer of Checkmate. We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family." "The unique combination of a differentiated Toll-like receptor 9 with other antibody-based oncology agents may result in increased clinical benefit and provide new treatment options for patients in need. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. "As we continue to advance and expand our research efforts in immuno-oncology, the acquisition of Checkmate will add a promising new modality to Regeneron's toolkit of potential approaches for difficult-to-treat cancers," said Leonard S. The proposed acquisition values Checkmate at a total equity value of approximately $250 million.Ĭheckmate's lead investigational candidate is vidutolimod, an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonist delivered in a virus-like particle. (NASDAQ: CMPI), a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer, today announced a definitive agreement for the acquisition of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock. (NASDAQ: REGN) and Checkmate Pharmaceuticals, Inc. > Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer > Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy > Proposed ~$250 million all-cash acquisition strengthens Regeneron's portfolio of diverse and combinable immuno-oncology candidates "Press Release: Regeneron to Acquire Checkmate Pharmaceuticals and Its Investigational Immune Activator for Potential Use in Multiple Tumor Types". VLP technology (virus-like particle technology) We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.Financing › Details Checkmate–Regeneron: investment, 202204– acquisition $250m cash tender offer at $10.5/share ANNOUNCEDĬheckmate Pharmaceuticals Inc. InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. (Note: You may have to copy this link into your browser then press the key.) To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. InvestorsObserver (PRNewsfoto/InvestorsObserver) (PRNewswire)
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |